IDEXX LABORATORIES INC /DE Q3 FY2026 earnings call

• Innovation & Product Launches: Strong momentum for InView DX, with nearly half of Q3 placements being international. Added nucleated red blood cells, eccentricites, and Fine Needle Aspirate (FNA) capabilities to the menu. Launched Catalyst ProBMP, the first dual-species quantitative cardiac test at point-of-care. Expanded CancerDx from a single test to a multi-cancer panel including canine mast cell tumor detection.
• Commercial Execution: Record Q3 instrument placements. High customer retention in CAG diagnostics (high 90s globally). Successful completion of international expansions in France, Spain, South Korea, and Canada ahead of schedule.
• Covet Acquisition: Completed in September. Covet is an AI-native ambient listening and clinical workflow software provider with a ~$20 million annualized revenue run rate. Integration aims to enhance diagnostic utilization and practice efficiency.
• Diagnostic Utilization Trends: U.S. same-store clinical visits declined an estimated 1.8%, but CAG Diagnostics recurring revenue grew significantly faster (+9.6%), indicating that diagnostic frequency per visit is increasing despite flat or declining visit volumes. Aging pet demographics continue to support demand.
• Reference Lab Growth: Global reference lab revenues grew 10% organically, led by volume gains from net new customers and increased utilization of broader testing menus like CancerDx.

Companion Animal Diagnostics (CAG): Organic revenue grew 10%, driven by 11% organic growth in CAG Diagnostics recurring revenues. CAG Diagnostics recurring revenue saw 9.6% growth in the U.S. and 14% internationally. Key drivers included strong instrument placements (5,780 units globally, including 1,904 InView DX analyzers) and increased utilization of innovations like CancerDx and Catalyst ProBMP. Water Business: Organic revenue increased 8%. Livestock, Poultry, and Dairy (LPD): Organic revenue increased 3%. Software: Organic revenue grew 10%, supported by recurring revenue growth and strong placements of the DR50 Plus platform. The acquisition of Covet added approximately $5 million in annualized revenue run rate.

• Full-Year Revenue: Raised to $4.741 billion - $4.767 billion (midpoint up $32 million). Reported revenue growth expected to be 10.1% - 10.8%.
• Organic Revenue Growth: Updated outlook is 9.3% - 10.0%. CAG Diagnostics recurring revenue growth expected to be 10.3% - 11.0%.
• Earnings Per Share (EPS): Increased to $14.96 - $15.16 per share (midpoint up $0.25). Reflects 15% - 16% comparable EPS growth, partially offset by dilution from the Covet acquisition.
• Operating Margin: Updated reported operating margin outlook is 32.1% - 32.3% for the full year. Includes ~30 basis points of negative impact from Covet integration/amortization.
• Free Cash Flow Conversion: Updated outlook is 95% - 100% of net income.
• Q4 Specifics: Implied reported revenue growth includes a ~70 basis point headwind from foreign currency. Expected reported operating margins for Q4 are 28.4% - 29.3%.

• Foreign Exchange Sensitivity: A 1% strengthening of the U.S. dollar would reduce revenue by approximately $4 million and EPS by 2 cents per share for the remainder of the year.
• Macroeconomic Factors: Muted puppy and kitten adoption levels due to macro challenges, though aging pet trends provide a counterbalance.
• Integration Risks: Costs and potential operational disruptions related to the integration of the Covet acquisition, including amortization and transaction costs.
• Competitive Landscape: Ongoing competition in the veterinary diagnostics and software sectors, requiring continuous innovation and commercial execution to maintain market share.

Q: Analyst asked why organic growth guidance was raised to ~10% despite stagnant U.S. vet visits, and requested details on puppy vs. older dog trends. / A: Management stated growth is volume-led, driven by innovation (InView DX, CancerDx), commercial execution, and positive pet demographic shifts (aging pets). They clarified that while puppy/kitten adoptions are muted, the aging cohort drives non-wellness diagnostic demand. Crucially, they noted that diagnostic growth no longer relies on overall visit growth, as practices are increasing testing frequency per visit even if total visits decline.

Q: Analyst asked about long-term InView DX placement assumptions given strong early uptake and whether 2027 operating margin expansion should be adjusted due to Covet acquisition impacts. / A: CEO confirmed they are on track to exceed the 5,500 unit placement goal for 2026 and the 20,000 unit five-year goal, citing strong international demand and expanded menu value (e.g., FNA). CFO clarified that while Covet introduces ~30 bps of margin dilution from integration/amortization, it is factored into current guidance. He maintained confidence in achieving 50-100 bps of annual operating margin expansion over the long term, viewing Covet as a multiplier for both software revenue and diagnostic utilization.

Q: Analyst asked about the magnitude of macro sensitivity baked into guidance and how Ref Lab growth is driven (market share vs. utilization). / A: CFO stated macro trends have been consistent with prior estimates, with no significant shift in demand trends during the quarter. CEO explained Ref Lab growth is broad-based, driven by investments in local service networks, sophisticated technology, and innovation (e.g., CancerDx). He highlighted that >20% of CancerDx runs come from non-primary lab customers, driving new customer acquisition and deeper engagement through a 'total solution' approach across point-of-care, labs, and software.

Q: Analyst asked about pricing resilience in diagnostics versus pharma and the strategy behind affordable CancerDx pricing ($15). / A: CEO emphasized focusing on price relative to value created rather than maximizing price. He highlighted that affordable screening (e.g., $15 CancerDx with blood work) drives higher wellness blood work inclusion and overall practice revenue, citing examples of corporate and independent practices seeing high adoption rates. CFO reinforced consistent pricing expectations set early in the year, noting the strategy expands the sector through volume rather than price hikes.

Q: Analyst asked about the revenue per analyzer range for InView DX and future placement opportunities globally. / A: CEO confirmed InView DX remains comfortably within the $3,500-$5,500 annual recurring revenue range per instrument, encompassing ear cytology, blood morphology, and now FNA. He noted that as FNA rolls out broadly, there is upside potential balanced by global expansion. He stated they are in 'full worldwide launch mode' for InView DX with significant remaining headroom for placements internationally and in the U.S.